GenoType MTBDRplus assay for screening and characterization of isoniazid and rifampicin resistance-associated mutations in multidrug-resistant Mycobacterium tuberculosis from India

Abstract

To the best of our knowledge this is the largest study evaluating the GenoType-MTBDR line probe assay from India. We have studied the prevalence of mutations encoding rifampicin and isoniazid resistance in different patient groups based on criteria for multidrug resistance (MDR) suspicion. The translational impact of this study is in the design of customized country- or region-wise line probe assay strips. The identification of a few mutations in particular patient groups and the detection of wild type deletion mutants with no observable mutations both point toward the need for such customization enabling us to combat the rising trend of MDR tuberculosis.

Comparison of Quantamatrix Multiplexed Assay Platform and GenoType MTBDR Assay Using Smear-Positive Sputum Specimens From Patients With Multidrug- Resistant/Extensively Drug-Resistant Tuberculosis in South Korea

“…Many specific mutations associated with drug resistance have been described (Kapur et al, 1994; Somoskovi et al, 2001; Palomino and Martin, 2014; Miotto et al, 2015). Molecular assays targeting these mutations have become crucial supplements, providing rapid screening of drug resistance (Sethi et al, 2017). Thus, the World Health Organization (WHO) has recommended the line probe assays (LPAs), including GenoType MTBDR plus and MTBDR sl (Hain Lifescience, Nehren, Germany), for the rapid screening of MDR- and XDR-TB.…”